Search Press releases Keywords From To 31 Oct 2024 UCB Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2024 Read More 22 Oct 2024 UCB Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting Read More 14 Oct 2024 UCB receives U.S. FDA approval for 320 mg single-injection device presentations of BIMZELX[®] (bimekizumab-bkzx) Read More 11 Oct 2024 UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and MGFA Scientific Session Read More 10 Oct 2024 Transparency notification BlackRock, Inc. Read More 9 Oct 2024 Transparency notification BlackRock, Inc. Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
